Search Results - "Valantine H"

Proliferation Signal Inhibitors in Transplantation: Questions at the Cutting Edge of Everolimus Therapy

Authors: Chapman, J.R. Valantine, H. Albanell, J. et al.

Source: Transplantation Proceedings. Dec2007, Vol. 39 Issue 10, p2937-2950. 14p.

Everolimus is associated with a reduced incidence of CMV infection in heart transplantation.

Authors: Dorent, R. Valantine, H. Parameshwar, J. et al.

Source: Journal of Heart & Lung Transplantation. Jan2003 Supplement, Vol. 22, pS141-S142. 1p.

(1637) - Serum Cell-Free DNA Associated with De Novo Cardiac Allograft Vasculopathy but not Donor Derived.

Authors: Brashear, T. Skoda, A.A. Kim, J. et al.

Source: Journal of Heart & Lung Transplantation. 2026 Supplement, Vol. 45 Issue 5, p749-749. 1p.

(1639) - Cell-Free DNA as a Non-Invasive Marker to Identify Wait-List Patients at Risk of Status Progression.

Authors: Nadella, N. Andargie, T. Fraser, E. et al.

Source: Journal of Heart & Lung Transplantation. 2026 Supplement, Vol. 45 Issue 5, p750-750. 1p.

Calcineurin inhibitors and post-transplant hyperlipidaemias.

Authors: Moore, R. Hernandez, D. Valantine, H.

Source: Drug Safety. Jul2001, Vol. 24 Issue 10, p755-766. 12p.

The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation.

Authors: Farrero Torres, M. Pando, M.J. Luo, C. et al.

Source: Clinical Transplantation. Nov2017, Vol. 31 Issue 11, pn/a-N.PAG. 10p.

Transdisciplinary translational science and the case of preterm birth.

Authors: Stevenson, D K Shaw, G M Wise, P H et al.

Source: Journal of Perinatology. Apr2013, Vol. 33 Issue 4, p251-258. 8p. 3 Diagrams, 1 Chart.

Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.

Authors: Epailly, E. Albanell, J. Andreassen, A. et al.

Source: Clinical Transplantation. Sep/Oct2011, Vol. 25 Issue 5, pE475-E486. 12p.

(863) - Sex Differences in Circulating microRNAs After Heart Transplantation on Behalf of the GRAfT Investigators.

Authors: DeFilippis, E. Bagchi, P. Mercado, A. et al.

Source: Journal of Heart & Lung Transplantation. 2025 Supplement, Vol. 44 Issue 4, pS406-S406. 1p.

(340) - Plasma Cell-Free DNA Chromatin Immunoprecipitation Distinguishes Acute Rejection Subtypes After Heart Transplantation.

Authors: Jang, M. Oluwayiose, O. Andargie, T. et al.

Source: Journal of Heart & Lung Transplantation. 2024 Supplement, Vol. 43 Issue 4, pS175-S176. 2p.

(201) - Cell-Free DNA Identifies High-Risk Donor Specific Antibodies in Heart Transplant Recipients.

Authors: Goldberg, J. Xu, Y. Tian, X. et al.

Source: Journal of Heart & Lung Transplantation. 2024 Supplement, Vol. 43 Issue 4, pS107-S108. 2p.

(659) - Cell-Free DNA to Unveil Potential Mechanisms of Racial Disparities in Lung Transplant.

Authors: Sanders, A.A. Andargie, T. Alnababteh, M. et al.

Source: Journal of Heart & Lung Transplantation. 2024 Supplement, Vol. 43 Issue 4, pS319-S319. 1p.

(59) - Myocardial Offloading with a Left Ventricular Assist Device Reduces End Organ Injury.

Authors: Andargie, T. Hill, T. Park, A. et al.

Source: Journal of Heart & Lung Transplantation. 2024 Supplement, Vol. 43 Issue 4, pS37-S37. 1p.

Cell-Free DNA Enhances Pathologist Interrater Reliability at the Assessment of Acute Rejection on Endomyocardial Biopsy, on Behalf of the GRAfT Investigators.

Authors: Mehta, A. Goldberg, J. Bagchi, P. et al.

Source: Journal of Heart & Lung Transplantation. 2023 Supplement, Vol. 42, pS108-S109. 2p.

Granulocyte Colony-Stimulating Factor Therapy Is Associated With a Reduced Incidence of Acute Rejection Episodes or Allograft Vasculopathy in Heart Transplant Recipients.

Authors: Vrtovec, B. Haddad, F. Pham, M. et al.

Source: Transplantation Proceedings. Jul2013, Vol. 45 Issue 6, p2406-2409. 4p.

Decisions, decisions: how program diversity influences residency program choice.

Authors: Ku MC Li YE Prober C et al.

Source: Journal of the American College of Surgeons. Aug2011, Vol. 213 Issue 2, p294-305. 12p.

Everolimus (Certican) in Heart Transplantation: Optimizing Renal Function Through Minimizing Cyclosporine Exposure

Authors: Lehmkuhl, H. Ross, H. Eisen, H. et al.

Source: Transplantation Proceedings. Dec2005, Vol. 37 Issue 10, p4145-4149. 5p.

Improving outcomes in heart transplantation: The potential of proliferation signal inhibitors

Authors: Eisen, H. Kobashigawa, J. Starling, R.C. et al.

Source: Transplantation Proceedings. May2005 Supplement 1, Vol. 37, p4-17. 14p.

Racial Differences in Immunosuppression and Lung Transplant Outcomes.

Authors: Charya, A. Jang, M. Sun, J. et al.

Source: Journal of Heart & Lung Transplantation. 2021 Supplement, Vol. 40 Issue 4, pS157-S158. 2p.

Characteristics of Urine Cell-Free DNA in Heart and Lung Transplant.

Authors: Bhatti, K. Agbor-Enoh, S. Tunc, I. et al.

Source: Journal of Heart & Lung Transplantation. Apr2019 Supplement, Vol. 38, pS245-S246. 2p.